Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results

Biohaven reported a Q3 2026 net loss of $129.3 million ($0.86 per share), down from $173.4 million ($1.64 per share) a year earlier; R&D expenses fell to $101.9 million from $141.2 million. The company announced licensing deals providing up to $100 million from Ono, including $80 million received, and $400 million in cash consideration from SK Biopharmaceuticals, subject to closing; it had $164.0 million in cash, securities and restricted cash at September 30. Pipeline and regulatory updates included FDA acceptance of the Vyglxia resubmission with a 1Q 2027 goal date, while opakalim enrollment remains on partial clinical hold pending nonclinical studies; topline RISE 3 data remain on track for 2H 2026.

Analysis

The key change is a reduction in financing risk, not proof of pipeline value: closing the SK transaction would materially improve liquidity while shifting Kv7 development costs and much of the asset’s upside to the partner. That makes the fully enrolled RISE 3 readout unusually important—positive data could validate retained royalty value; a safety or efficacy setback would leave BHVN with more cash but a thinner near-term catalyst set. The metabolite-related enrollment hold remains a material overhang for the broader Kv7 platform even if RISE 3 timing holds.

Over the next few weeks, watch for SK closing and the promised nonclinical update; delays would reopen funding and execution concerns. RISE 3 data and the FDA advisory committee process for Vyglxia are the principal binary catalysts into 1Q27. The SCA review has regulatory upside, but the advisory committee creates a meaningful reversal risk. Over 6–18 months, MoDE/TRAP value depends on execution in pivotal trials and whether regional partners can convert licenses into development progress; upfront payments alone do not validate efficacy or commercial demand.

Contrarian read: the cash infusion may be treated as a clean de-risking event, but it monetizes assets while BHVN retains substantial clinical and operating risk. Conversely, the current Kv7 hold may be over-penalized if the issue proves rodent-specific and RISE 3 succeeds. REGN’s drug-supply role in one exploratory combination cohort is not, on these facts, a material earnings catalyst.

Key Decisions for Investors

• For BHVN, consider only a small, defined-risk bullish call spread into RISE 3 if implied volatility and premium are reasonable; avoid an unhedged event-sized position. The thesis is a positive readout plus SK closing; cut or stand aside if the closing slips or the nonclinical update extends the hold.
• Do not treat the SK headline amount as fully available today: verify closing and receipt of the $350 million payment, with the remaining $50 million due later. Track cash, quarterly operating cash use, debt obligations, and share count before underwriting runway or dilution risk.
• Keep the SCA advisory committee as a separate catalyst: positive external-panel feedback could support the 1Q27 review, while a negative recommendation or FDA request for further evidence would undermine the regulatory thesis. Reassess when the meeting date and briefing materials are published.
• No actionable REGN trade from the supply agreement alone; the company is providing clinical supply, while Biohaven funds the study. Revisit only if subsequent data or commercial terms establish a meaningful economic contribution.